Co-Authors
This is a "connection" page, showing publications co-authored by HELEN HESLOP and ANDRAS HECZEY.
Connection Strength
0.924
-
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma. Res Sq. 2024 Apr 11.
Score: 0.246
-
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. 2024 Apr 03.
Score: 0.246
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.218
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.153
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 May 08.
Score: 0.062